Market News

5 Penny Stocks Insiders Are Buying


Motley Fool

1 Cancer Stock on Buyout Watch in 2022

The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. First, Pfizer (NYSE: PFE) and Moderna are both flush with cash thanks to their novel coronavirus vaccines. Third, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Pfizer, and Sanofi are all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios.

Elon Musk says Tesla Model S Plaid may launch in China in March

Previous article

Deere’s Strike Is Over, but Order Backlog, Higher Costs Remain

Next article

You may also like


Leave a reply

Your email address will not be published.

More in Market News